Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002

Results of the HAEMACARE project

Rafael Marcos-Gragera, Claudia Allemani, Carmen Tereanu, Roberta de Angelis, Riccardo Capocaccia, Marc Maynadie, Stefano Luminari, Stefano Ferretti, Tom Børge Johannesen, Risto Sankila, Marja Liisa Karjalainen-Lindsberg, Arianna Simonetti, Maria Carmen Martos, Martine Raphaël, Pilar Giraldo, Milena Sant

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. Conclusions This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.

Original languageEnglish
Pages (from-to)720-728
Number of pages9
JournalHaematologica
Volume96
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Survival
Neoplasms
Hematologic Neoplasms
Registries
Survival Rate
Benchmarking
International Classification of Diseases
Survival Analysis
Patient Care
Public Health
Databases
Population

Keywords

  • Lymphoid malignancies
  • Outcome
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002 : Results of the HAEMACARE project. / Marcos-Gragera, Rafael; Allemani, Claudia; Tereanu, Carmen; de Angelis, Roberta; Capocaccia, Riccardo; Maynadie, Marc; Luminari, Stefano; Ferretti, Stefano; Johannesen, Tom Børge; Sankila, Risto; Karjalainen-Lindsberg, Marja Liisa; Simonetti, Arianna; Martos, Maria Carmen; Raphaël, Martine; Giraldo, Pilar; Sant, Milena.

In: Haematologica, Vol. 96, No. 5, 05.2011, p. 720-728.

Research output: Contribution to journalArticle

Marcos-Gragera, R, Allemani, C, Tereanu, C, de Angelis, R, Capocaccia, R, Maynadie, M, Luminari, S, Ferretti, S, Johannesen, TB, Sankila, R, Karjalainen-Lindsberg, ML, Simonetti, A, Martos, MC, Raphaël, M, Giraldo, P & Sant, M 2011, 'Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: Results of the HAEMACARE project', Haematologica, vol. 96, no. 5, pp. 720-728. https://doi.org/10.3324/haematol.2010.034264
Marcos-Gragera R, Allemani C, Tereanu C, de Angelis R, Capocaccia R, Maynadie M et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: Results of the HAEMACARE project. Haematologica. 2011 May;96(5):720-728. https://doi.org/10.3324/haematol.2010.034264
Marcos-Gragera, Rafael ; Allemani, Claudia ; Tereanu, Carmen ; de Angelis, Roberta ; Capocaccia, Riccardo ; Maynadie, Marc ; Luminari, Stefano ; Ferretti, Stefano ; Johannesen, Tom Børge ; Sankila, Risto ; Karjalainen-Lindsberg, Marja Liisa ; Simonetti, Arianna ; Martos, Maria Carmen ; Raphaël, Martine ; Giraldo, Pilar ; Sant, Milena. / Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002 : Results of the HAEMACARE project. In: Haematologica. 2011 ; Vol. 96, No. 5. pp. 720-728.
@article{179c903ef7c74099b4e8e16652644647,
title = "Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: Results of the HAEMACARE project",
abstract = "Background The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results The 5-year relative survival rate was 57{\%} overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. Conclusions This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.",
keywords = "Lymphoid malignancies, Outcome, Survival",
author = "Rafael Marcos-Gragera and Claudia Allemani and Carmen Tereanu and {de Angelis}, Roberta and Riccardo Capocaccia and Marc Maynadie and Stefano Luminari and Stefano Ferretti and Johannesen, {Tom B{\o}rge} and Risto Sankila and Karjalainen-Lindsberg, {Marja Liisa} and Arianna Simonetti and Martos, {Maria Carmen} and Martine Rapha{\"e}l and Pilar Giraldo and Milena Sant",
year = "2011",
month = "5",
doi = "10.3324/haematol.2010.034264",
language = "English",
volume = "96",
pages = "720--728",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002

T2 - Results of the HAEMACARE project

AU - Marcos-Gragera, Rafael

AU - Allemani, Claudia

AU - Tereanu, Carmen

AU - de Angelis, Roberta

AU - Capocaccia, Riccardo

AU - Maynadie, Marc

AU - Luminari, Stefano

AU - Ferretti, Stefano

AU - Johannesen, Tom Børge

AU - Sankila, Risto

AU - Karjalainen-Lindsberg, Marja Liisa

AU - Simonetti, Arianna

AU - Martos, Maria Carmen

AU - Raphaël, Martine

AU - Giraldo, Pilar

AU - Sant, Milena

PY - 2011/5

Y1 - 2011/5

N2 - Background The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. Conclusions This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.

AB - Background The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age. Conclusions This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.

KW - Lymphoid malignancies

KW - Outcome

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=79955739676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955739676&partnerID=8YFLogxK

U2 - 10.3324/haematol.2010.034264

DO - 10.3324/haematol.2010.034264

M3 - Article

VL - 96

SP - 720

EP - 728

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -